SCHEMBL4412877

SCHEMBL4412877

COc1cc(OC)cc(-c2cc(=O)c3ccc(OCC(O)CNC(C)(C)C)cc3o2)c1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.49
KDM4E B2RXH2 2/20 0.49
ALDH1A1 P00352 2/20 0.49
HPGD P15428 2/20 0.49
HSD17B10 Q99714 2/20 0.49
MAOB P27338 2/20 0.49
USP2 O75604 1/20 0.49
MAPK1 P28482 1/20 0.49
RECQL P46063 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MEN1 O00255 2/20 0.48
TP53 P04637 2/20 0.48
CYP2C9 P11712 2/20 0.48
CYP2C19 P33261 2/20 0.48
KMT2A Q03164 2/20 0.48
CYP2D6 P10635 1/20 0.48
MAPT P10636 1/20 0.48
TNKS O95271 2/20 0.47
TNKS2 Q9H2K2 1/20 0.47
CYP19A1 P11511 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14293136 0.91 ADRB2 (0.49) CYP3A4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL4405303 0.90 PABPC1 (0.56) MAOB
SCHEMBL4399919 0.89 MEN1 (0.47) CYP3A4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL1483979 0.87 ADRB2 (0.52) MAOBMEN1KMT2ACYP2D6MAPT
SCHEMBL1483974 0.87 ADRB2 (0.52) MAOBMEN1KMT2ACYP2D6MAPT
SCHEMBL1483981 0.87 ADRB2 (0.52) MAOBMEN1KMT2ACYP2D6MAPT
SCHEMBL4405342 0.87 CYP3A4 (0.50) CYP3A4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL4405577 0.85 TNKS (0.52) CYP3A4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL11167135 0.83 MEN1 (0.54) MEN1KMT2ACYP2D6
SCHEMBL4407561 0.80 CYP1A1 (0.48) MEN1KMT2ACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1807408-B1 OXY SUBSTITUTED FLAVONES AS ANTIHYPERGLYCEMIC AND ANTIDYSLIPIDEMIC AGENTS COUNCIL SCIENT IND RES (IN) 2016-06-08 EP claimed
EP-1807408-A1 OXY SUBSTITUTED FLAVONES AS ANTIHYPERGLYCEMIC AND ANTIDYSLIPIDEMIC AGENTS Council of Scientific and Industrial Research (IN) 2007-07-18 EP claimed
US-20060178373-A1 Oxy substituted flavones as antihyperglycemic and antidyslipidemic agents COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2006-08-10 US claimed
WO-2006040621-A1 OXY SUBSTITUTED FLAVONES AS ANTIHYPERGLYCEMIC AND ANTIDYSLIPIDEMIC AGENTS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2006-04-20 WO claimed
EP-1807408-B1 OXY SUBSTITUTED FLAVONES AS ANTIHYPERGLYCEMIC AND ANTIDYSLIPIDEMIC AGENTS COUNCIL SCIENT IND RES (IN) 2016-06-08 EP disclosed
US-7635779-B2 Oxy substituted flavones as antihyperglycemic and antidyslipidemic agents COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2009-12-22 US disclosed
EP-1807408-A1 OXY SUBSTITUTED FLAVONES AS ANTIHYPERGLYCEMIC AND ANTIDYSLIPIDEMIC AGENTS Council of Scientific and Industrial Research (IN) 2007-07-18 EP disclosed
US-20060178373-A1 Oxy substituted flavones as antihyperglycemic and antidyslipidemic agents COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2006-08-10 US disclosed
WO-2006040621-A1 OXY SUBSTITUTED FLAVONES AS ANTIHYPERGLYCEMIC AND ANTIDYSLIPIDEMIC AGENTS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2006-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178373-A1 Oxy substituted flavones as antihyperglycemic and antidyslipidemic agents GPR119, LIPC, SLC5A2 CYP3A4 506/4885KDM4E 309/4885ALDH1A1 2333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.